Other languages Curis, Inc.

Equities

CRIS

US2312693094

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
14.71 ^USD	+1.66%		-0.94%	+15.37%

09/02	HC Wainwright Adjusts Price Target on Curis to $26 From $51, Maintains Buy Rating	MT
08/02	Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	09/02
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08/02
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	12/12
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	05/12
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
Curis, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	04/23/04
Taseko Mines Provided Financing Update For Florence Copper	14/23/14
Sector Update: Health Care Stocks Softer Late Thursday	07/23/07
Curis Says FDA Removes Partial Clinical Hold on Emavusertib Phase 1/2 Study	06/23/06
U.S. Food and Drug Administration Removes Partial Clinical Hold on Curis, Inc.'s TakeAim Leukemia Study RP2D Established At 300 Mg BID	06/23/06
Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	05/23/05
Curis, Inc. Appoints Jonathan Zung, Ph.D. as Chief Development Officer	05/23/05
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	13/23/13
Curis, Inc. Announces Additional Encouraging Clinical Data from TakeAim Leukemia Study of emavusertib (CA-4948) in Monotherapy R/R AML and hrMDS	12/22/12
Curis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10
Earnings Reaction History: CURIS INC, 83.3% Follow-Through Indicator, 6.4% Sensitive	09/22/09
Curis, Inc. Elects Anne E. Borgman as Class I Director	15/22/15
Curis, Inc. Announces Resignation of Lori A. Kunkel, M.D. from the Board of Directors, Effective September 30, 2022	23/22/23
Curis Says FDA Lifts Patient Enrollment Restriction in Monotherapy Phase of Cancer Treatment Trial	30/22/30

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Curis, Inc.

Equities

CRIS

US2312693094

Other languages

Filters